Stephen Falk

25.0k citations

123 papers · 11.4k indexed · 5 hit papers · h-index 38

Gastroenterology top 0.1%
Pulmonary and Respiratory Medicine top 0.1%
- Gastric Cancer Management and Outcomes 51
- Lung Cancer Treatments and Mutations 22
- Lung Cancer Diagnosis and Treatment 12
Oncology top 0.2%
- Colorectal Cancer Treatments and Studies 30
- Pancreatic and Hepatic Oncology Research 22
- Colorectal Cancer Surgical Treatments 10
Surgery top 0.2%
- Esophageal Cancer Research and Treatment 38
Cancer Research top 2%
- Cancer Genomics and Diagnostics 16

Co-authors: David Cunningham Timothy Iveson David B. Smith Ruth E. Langley Sally Stenning F. Lofts William Allum M. Nicolson
Cited by: Gastroenterology Pulmonary and Respiratory Medicine Oncology
Journals: Journal of Clinical Oncology (46 papers)British Journal of Cancer (11 papers)Annals of Oncology (9 papers)
Partner nations: United Kingdom United States Germany

In The Last Decade

Stephen Falk

121 papers receiving 11.2k citations

Hit Papers

5 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2013 The Lancet Oncology
2013 The Lancet Oncology
2013 The Lancet Oncology
2009 Journal of Clinical Oncology
2006 New England Journal of Medicine

Peers

Countries citing papers authored by Stephen Falk

Since Specialization

Citations

This map shows the geographic impact of Stephen Falk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Falk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Falk more than expected).

Fields of papers citing papers by Stephen Falk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Falk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Falk. The network helps show where Stephen Falk may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Stephen Falk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephen Falk Line = papers co-authored together Stephen Falk links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	211MO First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study Annals of Oncology ·一路宮,Daniel M. Halperin,Sten Myrehaug,Ümit Tümer,吉見健二郎,Pamela L. Kunz,Beth Chasen,敏世山田,森下英理子,D-Y. Oh,Changhoon Yoo,Stephen Falk,Geum Seong Jeong,Kulikowska Kamila Urszula,Ying Zhang,吉弘重久,Diego Ferone	2024	4
2	InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial Annals of Oncology ·Sheela Rao,Francesco Sclafani,Cathy Eng,Marianne G. Guren,Richard Adams,Al B. Benson,David Sebag‐Montefiore,Eva Segelov,Annette Bryant,Clare Peckitt,Kristin Looney,Michel Seymour,Jack Welch,Mark Saunders,R. Muirhead,John Bridgewater,Stephen Falk,Rob Glynne‐Jones,Dirk Arnold,David Cunningham	2018	16
3	Comparing open and minimally invasive surgical procedures for oesophagectomy in the treatment of cancer: the ROMIO (Randomised Oesophagectomy: Minimally Invasive or Open) feasibility study and pilot trial Health Technology Assessment ·Chris Metcalfe,Kerry Avery,Richard Berrisford,Paul Barham,Sian Noble,Anne Vincent Woelflin,George B. Hanna,Robert Goldin,Daisy Elliott,O Karame Ghassan,Grant Sanders,Andrew Hollowood,Stephen Falk,Dan Titcomb,Christopher G. Streets,Jenny Donovan,Jane Blazeby	2016	33
4	Surgical timing after chemoradiotherapy for rectal cancer, analysis of technique (STARRCAT): results of a feasibility multi-centre randomized controlled trial Techniques in Coloproctology ·(unknown),Jake Foster,Paul Ewings,Stephen Falk,Sanju Lama,Huw Roach,Nicholas P. West,Barbara Williams-Yesson,George B. Hanna,Nader Francis	2016	17
5	O-003 Long-term outcome from the SCALOP trial: a multi-centre randomized phase II trial of gemcitabine or capecitabine-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC) Annals of Oncology ·Chris Hurt,John Bridgewater,Stephen Falk,S. Cummins,Harpreet Wasan,Tom Crosby,G. Radhakrishna,Catherine Jephcott,Rajarshi Roy,Alec McDonald,Ruby Ray,Geetha Joseph,John Staffurth,R. A. Abrams,Gareth Griffiths,Tim Maughan,Somnath Mukherjee	2016	6
6	Outcome Reporting in Neoadjuvant Surgical Trials: A Systematic Review of the Literature and Proposals for New Standards JNCI Journal of the National Cancer Institute ·Natalie Blencowe,Laurenţiu Lucaci,Robert N. Whistance,Daniel Stevens,Newton A C S Wong,Stephen Falk,Jane Blazeby	2014	10
7	Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial The Lancet Oncology ·T. Crosby,Chris Hurt,Stephen Falk,Simon Gollins,Somnath Mukherjee,John Staffurth,Ruby Ray,Nadim Bashir,John Bridgewater,J I Geh,David Cunningham,Jane Blazeby,Rajarshi Roy,Tim Maughan,Gareth Griffiths	2013	272
8	Oesophageal Chemoradiotherapy in the UK—Current Practice and Future Directions Clinical Oncology ·Sarah Gwynne,Stephen Falk,Simon Gollins,B. M Owat,Adrian C Bateman,S. Cummins,Heike I. Grabsch,M. Hawkins,Colin J. McMahon,Somnath Mukherjee,G. Radhakrishna,Rajarshi Roy,Ricky A. Sharma,Emiliano Spezi,T. Crosby	2013	22
9	Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial Radiotherapy and Oncology ·Lisa Lowry,Paul Smith,Wendi Qian,Stephen Falk,Kim Benstead,Tim Illidge,David C. Linch,Martin Robinson,Andrew Jack,Peter Hoskin	2011	247
10	Induction Chemotherapy and Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Patients With Locally Advanced Inoperable Non–Small-Cell Lung Cancer: The MRC INCH Randomized Trial International Journal of Radiation OncologyBiologyPhysics ·M. Hatton,Matthew Nankivell,Curt Weikinn,Stephen Falk,Cheryl Pugh,Neal Navani,Richard Stephens,Mahesh Parmar	2010	26
11	Lung Cancer Stephen Falk,Chris Williams	2009	1
12	Routine Use of Continuous, Hyperfractionated, Accelerated Radiotherapy for Non–Small-Cell Lung Cancer: A Five-Center Experience International Journal of Radiation OncologyBiologyPhysics ·Omar Din,J.F. Lester,Alison Cameron,J. Ironside,V Iya,Stephen Falk,Rouaibia Farid,Sayyidah Alifah Rahmani,M. Hatton	2008	14
13	Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma British Journal of Cancer ·Stephen Falk,Alan Anthoney,Martin Eatock,Eric Van Cutsem,G.G. Baysarova,Hilary Glen,Juan W. Valle,Daniel W. Drolet,Donald G. Albert,D. Ferry,Jaffer A. Ajani	2006	10
14	Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancerbreakdown → New England Journal of Medicine ·David Cunningham,William Allum,Sally Stenning,J N Thompson,Cornelis J.�H. van de Velde,M. Nicolson,J.H. Scarffe,F. Lofts,Stephen Falk,Timothy Iveson,David B. Smith,Ruth E. Langley,Monica Verma,Simon Weeden,Yu Jo Chua	2006	4494
15	A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer Annals of Oncology ·D. Rea,J. W. R. Nortier,W.W. ten Bokkel Huinink,Stephen Falk,Dick J. Richel,Tim Maughan,Gerard Groenewegen,Jeff M. Smit,Neil Steven,Abner Quiroz Clemente,Dorothée Sémiond,Rachel Kerr,Cornelis J.A. Punt	2005	69
16	Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer BMC Cancer ·Shiqi Wang,Paul Ruff,Bernardo L. Rapoport,Stephen Falk,Francis Daniel,Conrad Jacobs,Neville Davidson,Josef Thaler,Shibi S. Kumar,James Carmichael	2004	8
17	What is the role of the insulin‐like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clinical Endocrinology ·Maria de Fátima Cavalcanti de Lima,Andre Marquis,Stafford L. Lightman,Stephen Falk,Vidya Mohamed‐Ali,L Armstrong,Ann Millar,Jeff M.P. Holly	2002	47
18	Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer British Journal of Cancer ·David Cunningham,Stephen Falk,D Jackson	2002	26
19	Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial BMJ ·Stephen Falk,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	2002	67
20	DNA Damaging and Cell Cycle Effects of the Topoisomerase I Poison Camptothecin in Irradiated Human Cells International Journal of Radiation Biology ·Stephen Falk,Paul J. Smith	1992	37

About Stephen Falk

Stephen Falk is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Gastroenterology, having authored 123 papers that have together received 11.4k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (51 papers), Esophageal Cancer Research and Treatment (38 papers), Colorectal Cancer Treatments and Studies (30 papers), Pancreatic and Hepatic Oncology Research (22 papers), Lung Cancer Treatments and Mutations (22 papers), Cancer Genomics and Diagnostics (16 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Colorectal Cancer Surgical Treatments (10 papers). The work is most often cited by research in Gastroenterology (2.1k citations), Pulmonary and Respiratory Medicine (7.7k citations) and Oncology (4.9k citations). Stephen Falk has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include David Cunningham, Timothy Iveson, David B. Smith, Ruth E. Langley, Sally Stenning, F. Lofts, William Allum, M. Nicolson, Monica Verma and J N Thompson. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, Annals of Oncology, The Lancet Oncology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact